# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Mumtaz Mahal (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-RE006-SYN
- Date: 2026-03-03
- Fictional facility: St. Posthumous Health Center
- Fictional author: Farzana Qureshi-Lindholm, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Prenatal visit at 21 weeks with the anatomy scan. **S**

## History of present illness

Mumtaz Mahal returns at 21 weeks 2 days, four weeks after her first intravenous iron dose, which she tolerated without reaction. She has more energy and is less breathless. It is the month of Ramadan; she has chosen not to fast during the pregnancy, as her faith allows, and plans to make up the days later. She feels the baby move every day. She takes aspirin and folic acid. She has no headache, visual change, abdominal pain, contractions, bleeding, or urinary symptoms. She had the anatomy scan this morning. **S**

| Element | Detail |
|---|---|
| Iron | First intravenous dose four weeks ago, no reaction; more energy |
| Fasting | Not fasting this Ramadan, by her own choice |
| Fetal movement | Daily |
| Scan | Anatomy scan this morning |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy better |
| Cardiovascular | Negative | Breathless only on several flights of stairs |
| Gastrointestinal | Negative | Nausea and constipation gone since stopping oral iron |
| Genitourinary | Negative | No bleeding, leaking fluid, or urinary symptoms |

4 systems reviewed. **S**

## Current medications

- Folic acid 0.4 mg oral tablet, one tablet by mouth daily **S**
- Aspirin 81 mg delayed-release tablet, one tablet by mouth at bedtime **S**

## Allergies

- No known allergy **S**

## Objective

BP 104/62 mmHg; pulse 88 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 61.9 kg; BMI 25.1 kg/m². All vital signs are synthetic.

Hemoglobin: 10.9 g/dL; Ferritin: 96 ng/mL; Estimated fetal weight: 410 g. All results are synthetic.

## Change since baseline

- Hemoglobin: 10.1 g/dL (low) at baseline, 10.9 g/dL at this visit **S**
- Ferritin: 9 ng/mL (low) at baseline, 96 ng/mL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; better color |
| Abdomen | Fundal height 21 cm; non-tender |
| Fetal | Scan: normal anatomy, estimated weight 410 g; fetal heart 148 per minute |
| Placenta | Posterior and fundal, lower edge more than 5 cm from the internal os; no lacunae; normal retroplacental clear zone |
| Urine dipstick | Protein negative |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Iron deficiency anemia in pregnancy** (O99.019). Hemoglobin 10.9 g/dL and ferritin 96 ng/mL four weeks after the first dose: responding. **S**
   - Second ferric carboxymaltose 750 mg dose today.
   - Blood count and ferritin at 27 weeks.
2. **Fourteenth pregnancy at 37** (O09.529). Normal anatomy; growth on the 50th centile. The placenta is fundal and clear of the cervix, and she has had no cesarean or other uterine surgery, so there is no placenta previa and the risk of placenta accreta spectrum is low; no repeat placental scan or MRI is needed. Blood pressure 104/62 mmHg. **S**
   - Continue aspirin and folic acid.
   - Glucose challenge, blood count, and Tdap at 27 weeks.
   - Visits every two weeks from 28 weeks.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure and urine protein | Every prenatal visit | Completed today | 104/62 mmHg; urine protein negative |
| Examination | Fetal heart and fundal height | Every prenatal visit | Completed today | Fetal heart 148 per minute; fundal height 21 cm |
| Examination | Weight gain | Every prenatal visit | Completed today | 61.9 kg, up 3.3 kg since intake |
| Laboratory | Hemoglobin and ferritin | At intake, four weeks after starting treatment, at 24 to 28 weeks, and before delivery | Completed today | Hemoglobin 10.9 g/dL and ferritin 96 ng/mL after the first intravenous dose; second dose today |
| Medication safety | Intravenous iron infusion safety | With each infusion | Completed today | No reaction to the first dose; second dose given with 30 minutes of observation, no reaction |
| Imaging | Detailed anatomy scan with placental location | At 18 to 22 weeks | Completed today | Normal anatomy; estimated weight 410 g; placenta posterior fundal, clear of the os; no signs of accreta |
| Imaging | Repeat placental scan at 32 weeks | Only if the placenta is low-lying or covers the os | Not indicated | Placenta well clear of the os |
| Medication safety | Low-dose aspirin | Daily from 12 to 16 weeks until delivery; review at every visit | Completed today | Taken nightly; no bruising or bleeding |
| Laboratory | Gestational diabetes screen | At 24 to 28 weeks | Due | Glucose challenge booked for 27 weeks |
| Survey | Perinatal mood screen (EPDS) | Each trimester | Due | Second-trimester screen at 27 weeks |
| Self-management | Postpartum hemorrhage risk assessment and birth plan | At intake, in the third trimester, and on admission for birth | Up to date | No placenta previa or accreta; risk factors remain grand multiparity and anemia, now improving |

## Goal progress

- Hemoglobin at least 11 g/dL with replete iron stores before delivery. In progress; target 2026-06-02. **S**
- An informed choice about aneuploidy screening by 14 weeks. Outcome by 2026-02-03: Chose cell-free DNA (low risk) with the nuchal translucency scan (1.7 mm); declined diagnostic testing. **S**
- Blood pressure below 140/90 mmHg with aspirin taken nightly from 13 weeks. In progress; target 2026-07-12. **S**
- A written delivery and postpartum hemorrhage plan agreed by 36 weeks, with birth planned in a hospital with a blood bank and operating theatre. In progress; target 2026-06-02. **S**
- A postpartum contraception choice and a plan for the interval before any future pregnancy, made on her own terms before delivery. In progress; target 2026-06-02. **S**

## Medication changes

- Started: Ferric carboxymaltose 750 mg in 250 mL 0.9% sodium chloride, intravenous infusion over 15 minutes (second of two doses) **S**

## Guideline basis

- Pregnancy at Age 35 Years or Older: ACOG Obstetric Care Consensus No. 11 (2022), American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine (Obstetrics & Gynecology)
- Anemia in Pregnancy: ACOG Practice Bulletin, Number 233 (2021), American College of Obstetricians and Gynecologists (Obstetrics & Gynecology)
- Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication (2021), U.S. Preventive Services Task Force
- Obstetric Care Consensus No. 7: Placenta Accreta Spectrum (2018), American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine (Obstetrics & Gynecology)

## Follow-up

- Prenatal visit at 27 weeks with the glucose challenge, blood count, and Tdap. **S**
- Next scheduled visit 2026-04-14: prenatal visit at 27 weeks: glucose challenge, blood count, and Tdap. **S**
